{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:41:02Z","timestamp":1793734862065,"version":"4.6.1"},"reference-count":93,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>C-reactive protein (CRP) is a member of the highly conserved pentraxin superfamily of proteins and is often used in clinical practice as a marker of infection and inflammation. There is now increasing evidence that CRP is not only a marker of inflammation, but also that destabilized isoforms of CRP possess pro-inflammatory and pro-thrombotic properties. CRP circulates as a functionally inert pentameric form (pCRP), which relaxes its conformation to pCRP* after binding to phosphocholine-enriched membranes and then dissociates to monomeric CRP (mCRP). with the latter two being destabilized isoforms possessing highly pro-inflammatory features. pCRP* and mCRP have significant biological effects in regulating many of the aspects central to pathogenesis of atherothrombosis and venous thromboembolism (VTE), by directly activating platelets and triggering the classical complement pathway. Importantly, it is now well appreciated that VTE is a consequence of thromboinflammation. Accordingly, acute VTE is known to be associated with classical inflammatory responses and elevations of CRP, and indeed VTE risk is elevated in conditions associated with inflammation, such as inflammatory bowel disease, COVID-19 and sepsis. Although the clinical data regarding the utility of CRP as a biomarker in predicting VTE remains modest, and in some cases conflicting, the clinical utility of CRP appears to be improved in subsets of the population such as in predicting VTE recurrence, in cancer-associated thrombosis and in those with COVID-19. Therefore, given the known biological function of CRP in amplifying inflammation and tissue damage, this raises the prospect that CRP may play a role in promoting VTE formation in the context of concurrent inflammation. However, further investigation is required to unravel whether CRP plays a direct role in the pathogenesis of VTE, the utility of which will be in developing novel prophylactic or therapeutic strategies to target thromboinflammation.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1002652","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T09:20:06Z","timestamp":1663060806000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":86,"title":["C-reactive protein, immunothrombosis and venous thromboembolism"],"prefix":"10.3389","volume":"13","author":[{"given":"Caroline","family":"Dix","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Zeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen U.","family":"Eisenhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen S. Cheung Tung","family":"Shing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy L.","family":"Nero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig J.","family":"Morton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karlheinz","family":"Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"McFadyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1080\/21548331.1982.11702332","article-title":"C-reactive protein and the acute phase response","volume":"27","author":"Gewurz","year":"1982","journal-title":"Adv Intern Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"14188","DOI":"10.1038\/ncomms14188","article-title":"Transitional changes in the CRP structure lead to the exposure of proinflammatory binding sites","volume":"8","author":"Braig","year":"2017","journal-title":"Nat Commun"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01351","article-title":"Dissociation of c-reactive protein localizes and amplifies inflammation: Evidence for a direct biological role of c-reactive protein and its conformational changes","volume":"9","author":"McFadyen","year":"2018","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/978-3-030-41769-7_20","article-title":"C-reactive protein and its structural isoforms: An evolutionary conserved marker and central player in inflammatory diseases and beyond","volume":"94","author":"McFadyen","year":"2020","journal-title":"Subcell Biochem"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0969-2126(99)80023-9","article-title":"The physiological structure of human c-reactive protein and its complex with phosphocholine","volume":"7","author":"Thompson","year":"1999","journal-title":"Structure"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M307764200","article-title":"The crystal structure of the globular head of complement protein C1q provides a basis for its versatile recognition properties","volume":"278","author":"Gaboriaud","year":"2003","journal-title":"J Biol Chem"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.114.302770","article-title":"Infusion of pharmaceutical-grade natural human c-reactive protein is not proinflammatory in healthy adult human volunteers","volume":"114","author":"Lane","year":"2014","journal-title":"Circ Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-3639.2011.00539.x","article-title":"Amyloid plaques dissociate pentameric to monomeric c-reactive protein: A novel pathomechanism driving cortical inflammation in alzheimer's disease","volume":"22","author":"Strang","year":"2012","journal-title":"Brain Pathol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/cvr\/cvs237","article-title":"Circulating microparticles generate and transport monomeric c-reactive protein in patients with myocardial infarction","volume":"96","author":"Habersberger","year":"2012","journal-title":"Cardiovasc Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1161\/CIRCULATIONAHA.113.007124","article-title":"Dissociation of pentameric to monomeric c-reactive protein localizes and aggravates inflammation: In vivo proof of a powerful proinflammatory mechanism and a new anti-inflammatory strategy","volume":"130","author":"Thiele","year":"2014","journal-title":"Circulation"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.108.190611","article-title":"Dissociation of pentameric to monomeric c-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques","volume":"105","author":"Eisenhardt","year":"2009","journal-title":"Circ Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20112322","article-title":"Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo","volume":"209","author":"von Bruhl","year":"2012","journal-title":"J Exp Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.121.318225","article-title":"Inflammation, infection and venous thromboembolism","volume":"128","author":"Colling","year":"2021","journal-title":"Circ Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.121.317187","article-title":"Caught at the scene of the crime: Platelets and neutrophils are conspirators in thrombosis","volume":"42","author":"Moon","year":"2022","journal-title":"Arteriosclerosis Thrombosis Vasc Biol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1126\/science.1092385","article-title":"Neutrophil extracellular traps kill bacteria","volume":"303","author":"Brinkmann","year":"2004","journal-title":"Science"},{"key":"B16","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nri3345","article-title":"Thrombosis as an intravascular effector of innate immunity","volume":"13","author":"Engelmann","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcm.2010.02.002","article-title":"Monomeric c-reactive protein generation on activated platelets: The missing link between inflammation and atherothrombotic risk","volume":"19","author":"Eisenhardt","year":"2009","journal-title":"Trends Cardiovasc Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1096\/fj.08-116962","article-title":"Monomeric c-reactive protein activates endothelial cells via interaction with lipid raft microdomains","volume":"23","author":"Ji","year":"2009","journal-title":"FASEB J"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000125527.41598.68","article-title":"Conformational rearrangement in c-reactive protein is required for proinflammatory actions on human endothelial cells","volume":"109","author":"Khreiss","year":"2004","journal-title":"Circulation"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.555318","article-title":"Topological localization of monomeric c-reactive protein determines proinflammatory endothelial cell responses","volume":"289","author":"Li","year":"2014","journal-title":"J Biol Chem"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.9.5355","article-title":"Loss of pentameric symmetry of c-reactive protein is associated with promotion of neutrophil-endothelial cell adhesion","volume":"167","author":"Zouki","year":"2001","journal-title":"J Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1084\/jem.192.2.193","article-title":"Platelet glycoprotein ibalpha is a counterreceptor for the leukocyte integrin mac-1 (CD11b\/CD18)","volume":"192","author":"Simon","year":"2000","journal-title":"J Exp Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.2.513.513","article-title":"C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor","volume":"82","author":"Cermak","year":"1993","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvr226","article-title":"Monomeric c-reactive protein is prothrombotic and dissociates from circulating pentameric c-reactive protein on adhered activated platelets under flow","volume":"92","author":"Molins","year":"2011","journal-title":"Cardiovasc Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12415","article-title":"Monomerization of c-reactive protein requires glycoprotein IIb-IIIa activation: Pentraxins and platelet deposition","volume":"11","author":"de la Torre","year":"2013","journal-title":"J Thromb Haemost."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1172\/JCI61303","article-title":"Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury","volume":"122","author":"Caudrillier","year":"2012","journal-title":"J Clin Invest"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-749879","article-title":"Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development","volume":"129","author":"Subramaniam","year":"2017","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.306853","article-title":"Cross talk pathways between coagulation and inflammation","volume":"118","author":"Foley","year":"2016","journal-title":"Circ Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01522","article-title":"Complement C1q enhances primary hemostasis","volume":"11","author":"Donat","year":"2020","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2015.251314","article-title":"Complement C3 and high risk of venous thromboembolism: 80517 individuals from the Copenhagen general population study","volume":"62","author":"Norgaard","year":"2016","journal-title":"Clin Chem"},{"key":"B31","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s10654-017-0238-y","article-title":"Time trends in incidence rates of venous thromboembolism in a large cohort recruited from the general population","volume":"32","author":"Arshad","year":"2017","journal-title":"Eur J Epidemiol."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.91.11.2844","article-title":"Molecular bases of the acute coronary syndromes","volume":"91","author":"Libby","year":"1995","journal-title":"Circulation"},{"key":"B33","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/s0140-6736(96)07591-5","article-title":"Production of c-reactive protein and risk of coronary events in stable and unstable angina. European concerted action on thrombosis and disabilities angina pectoris study group","volume":"1997","author":"Haverkate","year":"9050","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.97.5.425","article-title":"Plasma concentration of c-reactive protein and risk of developing peripheral vascular disease","volume":"97","author":"Ridker","year":"1998","journal-title":"Circulation"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.98.8.731","article-title":"Prospective study of c-reactive protein and the risk of future cardiovascular events among apparently healthy women","volume":"98","author":"Ridker","year":"1998","journal-title":"Circulation"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199704033361401","article-title":"Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men","volume":"336","author":"Ridker","year":"1997","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.eurheartj.a015068","article-title":"Serum c-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment","volume":"17","author":"Pietila","year":"1996","journal-title":"Eur Heart J"},{"key":"B38","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1161\/01.CIR.100.1.96","article-title":"C-reactive protein as a cardiovascular risk factor: More than an epiphenomenon","volume":"100","author":"Lagrand","year":"1999","journal-title":"Circulation"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/nature04672","article-title":"Targeting c-reactive protein for the treatment of cardiovascular disease","volume":"440","author":"Pepys","year":"2006","journal-title":"Nature"},{"key":"B40","doi-asserted-by":"publisher","first-page":"108165","DOI":"10.1016\/j.pharmthera.2022.108165","article-title":"Transitional changes in the structure of c-reactive protein create highly pro-inflammatory molecules: Therapeutic implications for cardiovascular diseases","volume":"235","author":"Zeller","year":"2022","journal-title":"Pharmacol Ther"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1001\/jama.286.1.64","article-title":"Effect of statin therapy on c-reactive protein levels: the pravastatin inflammation\/CRP evaluation (PRINCE): a randomized trial and cohort study","volume":"286","author":"Albert","year":"2001","journal-title":"JAMA"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0900241","article-title":"A randomized trial of rosuvastatin in the prevention of venous thromboembolism","volume":"360","author":"Glynn","year":"2009","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.109.198473","article-title":"C-reactive protein and risk of venous thromboembolism in the general population","volume":"30","author":"Zacho","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2004.00773.x","article-title":"C-reactive protein gene polymorphisms and the risk of venous thromboembolism: a haplotype-based analysis","volume":"2","author":"Zee","year":"2004","journal-title":"J Thromb Haemost"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.22.2703","article-title":"Association of polymorphisms in the CRP gene with circulating c-reactive protein levels and cardiovascular events","volume":"296","author":"Lange","year":"2006","journal-title":"JAMA"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.43.6.519-b","article-title":"Acute phase response and deep lower limb venous thrombosis","volume":"43","author":"Syrjala","year":"1990","journal-title":"J Clin Pathol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1614281","article-title":"CRP measured by a high sensitivity assay correlates with clinical probability (Wells score) testing for deep venous thrombosis","volume":"91","author":"Korte","year":"2004","journal-title":"Thromb Haemost"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1067\/mva.2002.121746","article-title":"Inflammatory response in the acute phase of deep vein thrombosis","volume":"35","author":"Roumen-Klappe","year":"2002","journal-title":"J Vasc Surg"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.186957","article-title":"C-reactive protein and risk of venous thromboembolism: results from a population-based case-crossover study","volume":"103","author":"Grimnes","year":"2018","journal-title":"Haematologica"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1614553","article-title":"Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions","volume":"81","author":"Kamphuisen","year":"1999","journal-title":"Thromb Haemost"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(02)01345-1","article-title":"Coagulation factors, inflammation markers, and venous thromboembolism: The longitudinal investigation of thromboembolism etiology (LITE)","volume":"113","author":"Tsai","year":"2002","journal-title":"Am J Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1160\/TH04-11-0745","article-title":"Basal high-sensitivity-C-reactive protein levels in patients with spontaneous venous thromboembolism","volume":"93","author":"Vormittag","year":"2005","journal-title":"Thromb Haemost"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1160\/TH09-04-0274","article-title":"C-reactive protein and venous thromboembolism. a prospective investigation in the ARIC cohort","volume":"102","author":"Folsom","year":"2009","journal-title":"Thromb Haemost"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1160\/TH-09-02-0104","article-title":"Cardiovascular risk factors in idiopathic compared to risk-associated venous thromboembolism: A focus on fibrinogen, factor VIII, and high-sensitivity c-reactive protein (hs-CRP)","volume":"102","author":"Luxembourg","year":"2009","journal-title":"Thromb Haemost"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.011866","article-title":"Arterial cardiovascular risk factors and venous thrombosis: results from a population-based, prospective study (the HUNT 2)","volume":"95","author":"Quist-Paulsen","year":"2010","journal-title":"Haematologica"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.034991","article-title":"High-sensitivity c-reactive protein is not a risk factor for venous thromboembolism: The tromso study","volume":"96","author":"Hald","year":"2011","journal-title":"Haematologica"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1111\/jth.12742","article-title":"Inflammation markers and incident venous thromboembolism: The REasons for geographic and racial differences in stroke (REGARDS) cohort","volume":"12","author":"Olson","year":"2014","journal-title":"J Thromb Haemost"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-017-0277-4","article-title":"Serum c-reactive protein increases the risk of venous thromboembolism: A prospective study and meta-analysis of published prospective evidence","volume":"32","author":"Kunutsor","year":"2017","journal-title":"Eur J Epidemiol."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13369","article-title":"C-reactive protein, obesity, and the risk of arterial and venous thrombosis","volume":"14","author":"Horvei","year":"2016","journal-title":"J Thromb Haemost"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.10.1182","article-title":"Cardiovascular risk factors and venous thromboembolism incidence: The longitudinal investigation of thromboembolism etiology","volume":"162","author":"Tsai","year":"2002","journal-title":"Arch Intern Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2016.06.012","article-title":"Body size measures, hemostatic and inflammatory markers and risk of venous thrombosis: The longitudinal investigation of thromboembolism etiology","volume":"144","author":"Cushman","year":"2016","journal-title":"Thromb Res"},{"key":"B63","doi-asserted-by":"publisher","first-page":"27478","DOI":"10.1038\/srep27478","article-title":"Platelet-monocyte aggregates and c-reactive protein are associated with VTE in older surgical patients","volume":"6","author":"Shih","year":"2016","journal-title":"Sci Rep"},{"key":"B64","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1186\/s13018-020-02089-4","article-title":"Age over 65 years and high levels of c-reactive protein are associated with the risk of preoperative deep vein thrombosis following closed distal femur fractures: A prospective cohort study","volume":"15","author":"Zhang","year":"2020","journal-title":"J Orthop Surg Res"},{"key":"B65","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12893-016-0128-3","article-title":"28 day post-operative persisted hypercoagulability after surgery for benign diseases: A prospective cohort study","volume":"16","author":"Ulrych","year":"2016","journal-title":"BMC Surg"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.080493","article-title":"Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy","volume":"179","author":"Rodger","year":"2008","journal-title":"CMAJ"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.925214","article-title":"Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: The Vienna prediction model","volume":"121","author":"Eichinger","year":"2010","journal-title":"Circulation"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2012.04735.x","article-title":"Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: A proposed prediction score (DASH)","volume":"10","author":"Tosetto","year":"2012","journal-title":"J Thromb Haemost"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002364","article-title":"Long-term treatment of venous thromboembolism","volume":"135","author":"Kearon","year":"2020","journal-title":"Blood"},{"key":"B70","volume-title":"Inflammation markers, d-dimer and the risk of recurrent venous thrombosis","author":"Roshani","year":"2012"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.20452\/pamw.3311","article-title":"Iron deficiency: A novel risk factor of recurrence in patients after unprovoked venous thromboembolism","volume":"126","author":"Potaczek","year":"2016","journal-title":"Pol Arch Med Wewn."},{"key":"B72","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.trsl.2020.06.012","article-title":"Mechanisms and biomarkers of cancer-associated thrombosis","volume":"225","author":"Kim","year":"2020","journal-title":"Transl Res"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.209114","article-title":"The khorana score for prediction of venous thromboembolism in cancer patients: A systematic review and meta-analysis","volume":"104","author":"Mulder","year":"2019","journal-title":"Haematologica"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N Engl J Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-009-9116-4","article-title":"Serum c-reactive protein (CRP) levels in cancer patients are linked with tumor burden and are reduced by anti-hypertensive medication","volume":"32","author":"Koukourakis","year":"2009","journal-title":"Inflammation"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.744129","article-title":"C-reactive protein and cancer: Interpreting the differential bioactivities of its pentameric and monomeric, modified isoforms","volume":"12","author":"Potempa","year":"2021","journal-title":"Front Immunol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.7150\/thno.19900","article-title":"Targeting activated platelets: A unique and potentially universal approach for cancer imaging","volume":"7","author":"Yap","year":"2017","journal-title":"Theranostics"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S261718","article-title":"Clinical evaluation for the role of high-sensitivity c-reactive protein in combination with d-dimer and wells score probability test to predict the incidence of deep vein thrombosis among cancer patients","volume":"13","author":"Setiawan","year":"2020","journal-title":"Int J Gen Med"},{"key":"B80","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1093\/annonc\/mdj068","article-title":"Risk factors for venous thromboembolic events in cancer patients","volume":"17","author":"Kroger","year":"2006","journal-title":"Ann Oncol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/j.1538-7836.2010.04069.x","article-title":"Thrombosis risk and survival in cancer patients with elevated c-reactive protein","volume":"9","author":"Kanz","year":"2011","journal-title":"J Thromb Haemost"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13596","article-title":"Update on guidelines for the management of cancer-associated thrombosis","volume":"26","author":"Streiff","year":"2021","journal-title":"Oncologist"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0269-5","article-title":"D-dimer and high-sensitivity c-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis","volume":"119","author":"Jara-Palomares","year":"2018","journal-title":"Br J Cancer"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.4564","article-title":"Tissue factor as a predictor of recurrent venous thromboembolism in malignancy: Biomarker analyses of the CATCH trial","volume":"35","author":"Khorana","year":"2017","journal-title":"J Clin Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17664","article-title":"COVID-19 and immunothrombosis: emerging understanding and clinical management","volume":"194","author":"Shaw","year":"2021","journal-title":"Br J Haematol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.120.317447","article-title":"The emerging threat of (Micro)Thrombosis in COVID-19 and its therapeutic implications","volume":"127","author":"McFadyen","year":"2020","journal-title":"Circ Res"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12439","article-title":"Risk of venous thromboembolism in patients with COVID-19: A systematic review and meta-analysis","volume":"4","author":"Nopp","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2020.04.013","article-title":"Incidence of thrombotic complications in critically ill ICU patients with COVID-19","volume":"191","author":"Klok","year":"2020","journal-title":"Thromb Res"},{"key":"B89","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1182\/blood.2020006520","article-title":"COVID-19 and coagulation: Bleeding and thrombotic manifestations of SARS-CoV-2 infection","volume":"136","author":"Al-Samkari","year":"2020","journal-title":"Blood"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2020.09.017","article-title":"Biomarkers for the prediction of venous thromboembolism in critically ill COVID-19 patients","volume":"196","author":"Dujardin","year":"2020","journal-title":"Thromb Res"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1076029620982669","article-title":"Deep venous thrombosis in COVID-19 patients: A cohort analysis","volume":"26","author":"Cai","year":"2020","journal-title":"Clin Appl Thromb Hemost"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2021.01.003","article-title":"Incidence, risk factors, and thrombotic load of pulmonary embolism in patients hospitalized for COVID-19 infection","volume":"82","author":"Garcia-Ortega","year":"2021","journal-title":"J Infect"},{"key":"B93","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1056\/NEJMoa2105911","article-title":"Therapeutic anticoagulation with heparin in noncritically ill patients with covid-19","volume":"385","author":"Investigators","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1002652\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T09:20:10Z","timestamp":1663060810000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1002652\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,13]]},"references-count":93,"alternative-id":["10.3389\/fimmu.2022.1002652"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1002652","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,13]]},"article-number":"1002652"}}